1. Arndt IO, Dorozynsky L, Woody GE, McLellan AT, O'Brien CP. Desipramine treatment of cocaine dependence in methadone-maintained patients. Arch Gen Psychiatry 1992;49:888-893.

2. Benowitz NL. How toxic is cocaine? In: Cocaine: scientific and social dimensions. Chichester: John Wiley & Sons, Ciba Foundation Symposium 166, 1992;125-148.

3. Butynski W, Reda JL, Canova D, et al. State resources and services related to alcohol and drug abuse profile data. Washington, DC: National Association of State Alcohol and Drug Abuse Directors, 1991.

4. Caine SG, Koob GF. Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science 1993;260:1814-1816.

5. Carroll FI, Lewin AH, Boja JW, Kuhar MJ. Cocaine receptor: biochemical characterization and structure-activity relationships of cocaine analogues at the dopamine transporter. J Med Chem 1992;35:969-981.

6. Carroll ME, Lac ST, Acensio M, Kragh R. Fluoxetine reduces intravenous cocaine self-administration in rats. Pharmacol Biochem Behav 1990;35:237-244.

7. Chilcoat HD, Schutz CG. Racial/ethnic differences in crack use within neighborhoods. Addiction Res 1994; in press.

8. Chow JM, Menchen SL, Paul BD, Stein RJ. Vascular changes in the nasal submucosa of chronic cocaine addicts. Am J Forensic Med Pathol 1990;11:136-143.

9. Cunningham KA, Callahan PM. Monoamine reuptake inhibitors enhance the discriminative state induced by cocaine in the rat. Psychopharmacology 1991;104:177-180.

10. Cunningham KA, Paris JM, Goeders NE. Serotonin neurotransmission in cocaine sensitization. In: Kalivas PW, Samson HH, eds. The neurobiology of drug and alcohol addiction. New York: The New York Academy of Sciences, 1992;117-127.

11. Dackis CA, Gold MS. Pharmacological approaches to cocaine addiction. J Subst Abuse Treat 1985;2:139-145.

12. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988;85:5274-5278.

13. Dworkin SI, Smith JE. Neurobehavioral pharmacology of cocaine. In: Clouet D, Asghar K, Brown R, eds. Mechanisms of cocaine abuse and toxicity. Washington, DC: U.S. Government Printing Office, 1988;185-198.

14. Dwoskin LP, Peris J, Yasuda RP, Philpott K, Zahniser NR. Repeated cocaine administration results in supersensitivity of striatal D-2 autoreceptors to pergolide. Life Sci 1988;42:255-262.

15. Evans SM, Cone EJ, Marco AP, Henningfield JE. A comparison of the arterial kinetics of smoked and intravenous cocaine. In: Harris L, eds. Problems of drug dependence, 1992. Rockville, MD: U.S. Department of Health and Human Services, 1993;343.

16. Fischman MW, Foltin RW. The effects of desipramine maintenance on cocaine self-administration in humans. Psychopharmacology 1988;96:S20.

17. Foltin RW, Fischman MW. Ethanol and cocaine interactions in humans: cardiovascular consequences. Pharmacol Biochem Behav 1989;31:877-883.

18. Foltin RW, Fischman MW. Smoked and intravenous cocaine in humans: acute tolerance, cardiovascular and subjective effects. J Pharmacol Exp Ther 1991;257:247-261.

19. Gastfriend D, Mendelson J, Mello N, Teoh S, Reif S. Buprenorphine pharmacotherapy for concurrent heroin and cocaine dependence. Am J Addict 1993;2:269-278.

20. Gawin F, Allen D, Hurnblestone B. Outpatient treatment of "crack" cocaine smoking with flupenthixol decanoate. Arch Gen Psychiatry 1989;46:322-325.

21. Gawin FH, Kleber HD. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical observations. Arch Gen Psychiatry 1986;43:107-113.

22. Gawin FH, Kleber HD, Byck R, et al. Desipramine facilitation of initial cocaine abstinence. Arch Gen Psychiatry 1989;46:117-121.

23. Goeders NE, Smith JE. Intracranial cocaine self-administration into the medial prefrontal cortex increases dopamine turnover in the nucleus accumbens. J Pharmacol Exp Ther 1993;265:592-600.

24. Grilli M, Wright AG, Hanbauer I. Characterization of [3H]dopamine uptake sites and [3H]cocaine recognition sites in primary cultures of mesencephalic neurons during in vitro development. J Neurochem 1991;56:2108-2115.

25. Hearn WL, Flynn DD, Hime GW, et al. Cocaethylene: a unique cocaine metabolite displays high affinity for the dopamine transporter. J Neurochem 1991;56:698-701.

26. Hearn WL, Rose S, Wagner J, Ciarleglios A, Mash DC. Cocaethylene is more potent that cocaine in mediating lethality. Pharmacol Biochem Behav 1991;3:531-533.

27. Henry DJ, White FJ. Electrophysiological correlates of psychomotor stimulant-induced sensitization. In: Kalivas PW, Samson HH, eds. The neurobiology of drug and alcohol addiction. New York: The New York Academy of Sciences, 1992;654:88-100.

28. Hime GW, Hearn WL, Rose S, Cofino J. Analysis of cocaine and cocaethylene in blood and tissues by GD-NPD and GC-ion trap mass spectrometry. J Anal Toxicol 1991;15:241-245.

29. Hubner CB, Moreton JE. Effects of selective D1 and D2 dopamine antagonists on cocaine self-administration in the rat. Psychopharmacology 1991;105:151-156.

30. Hurd YL, Weiss F, Anden N-E, Koob GF, Ungerstedt U. Cocaine reinforcement and extracellular dopamine overflow in rat nucleus accumbens: an in vivo microdialysis study. Brain Res 1989;498:199-203.

31. Izenwasser S, Cox BM. Daily cocaine treatment produces a persistent reduction of [3H]dopamine uptake in vitro in rat nucleus accumbens but not in striatum. Brain Res 1990;531:338-341.

32. Jacobs IG, Roszler MH, Kelly JK, Klein MA, Kling GA. Cocaine abuse: neurovascular complications. Radiology 1989;170:223-227.

33. Johanson CE, Barrett JE. The discriminative stimulus effects of cocaine in pigeons. J Pharmacol Exp Ther 1993;267:1-8.

34. Johanson CE, Fischman MF. The pharmacology of cocaine related to its abuse. Pharmacol Rev 1989;41:3-52.

35. Johanson CE, Schuster CR. Animal models of drug self-administration. In: Mello NK, ed. Advances in substance abuse: behavioral and biological research. Greenwich, CT, JAI Press, 1981; 219-297.

36. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992;267:2750-2755.

37. Kalivas PW, Duffy P. Time course of extracellular dopamine and behavioral sensitization to cocaine. I. Dopamine axon terminals. J Neurosci 1993;13:266-275.

38. Kalivas PW, Duffy P. Time course of extracellular dopamine and behavioral sensitization to cocaine. II. Dopamine perikarya. J Neurosci 1993;13:276-284.

39. Kalivas PW, Sorg BA, Hooks MS. The pharmacology and neural circuitry of sensitization to psychostimulants. Behav Pharmacol 1993;4:315-334.

40. Kalivas PW, Striplin CD, Steketee JD, Klitenick MA, Duffy P. Cellular mechanisms of behavioral sensitization to drugs of abuse. In: Kalivas PW, Samson HH, eds. The neurobiology of drug and alcohol addiction. New York: The New York Academy of Sciences, 1992;654:128-135.

41. Kandel DB, Faust R. Sequences and stages in patterns of adolescent drug use. Arch Gen Psychiatry 1975;32:923-932.

42. Kandel DB, Yamaguchi K. From beer to crack: developmental patterns of involvement in drugs. Am J Public Health 1993;83:851-855.

43. Kilbey MM, Breslau N, Andreski P. Cocaine use and dependence in young adults: associated psychiatric disorders and personality traits. Drug Alcohol Depend 1992;29:283-290.

44. Kilty JE, Lorang D, Amara SG. Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science 1991;254:578-579.

45. Kitayama S, Shimada S, Xu H, Markham L, Donovan DM, Uhl GR. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc Natl Acad Sci USA 1992;89:7782-7785.

46. Kleven MS, Anthony EW, Woolverton WL. Pharmacological characterization of the discriminative stimulus effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther 1990;254:312-317.

47. Kleven MS, Woolverton WL, Seiden LS. Lack of long-term monoamine depletions following continuous or repeated exposure to cocaine. Brain Res Bull 1988;21:233-237.

48. Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science 1988;242:715-723.

49. Koob GF, Le HT, Creese I. The D1 dopamine receptor antagonist SCH 23390 increases cocaine self-administration in the rat. Neurosci Lett 1987;79:315-320.

50. Kosten RT, Morgan CM, Falcione J, Schottenfeld RS. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch Gen Psychiatry 1992;49:894-898.

51. Kuhar MJ, Ritz MC, Boja JW. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 1991;14:299-302.

52. Levin FR, Lehman AF. Meta-analysis of desipramine as an adjunct in the treatment of cocaine addiction. J Clin Psychopharmacol 1991;11:374-378.

53. Lillie-Blanton M, Anthony JC, Schuster CR. Probing the meaning of racial/ethnic group comparisons in crack-cocaine smoking. JAMA 1993;269:993-997.

54. Lindenbaum GA, Carroll SF, Daskal I, Kapusnick R. Patterns of alcohol and drug abuse in an urban trauma center: the increasing role of cocaine abuse. J Trauma 1989;29:1654-1658.

55. Loh EA, Roberts DCS. Break-points on a progressive ratio schedule reinforced by intravenous cocaine increase following depletion of forebrain serotonin. Psychopharmacology 1990;101:262-266.

56. Lutiger B, Graham K, Einarson TR, Koren G. Relationship between gestational cocaine use and pregnancy outcome: a meta-analysis. Teratology 1991;44:405-414.

57. Maldonado R, Robledo P, Chover AJ, Caine SB, Koob GF. D1 dopamine receptors in the nucleus accumbens modulate cocaine self-administration in the rat. Pharmacol Biochem Behav 1993;45:239-242.

58. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult outcome of hyperactive boys. Arch Gen Psychiatry 1993;50:565-576.

59. Markou A, Koob GF. Postcocaine anhedonia: an animal model of cocaine withdrawal. Neuropsychopharmacology 1991;4:17-26.

60. Mello NK, Mendelson JH, Bree MP, Lukas SE. Buprenorphine suppresses cocaine self-administration by rhesus monkeys. Science 1989;245:859-862.

61. Mendelson JH, Mello NK, Teoh SK, Elingboe J, Cochin J. Cocaine effects on pulsatile secretion of anterior pituitary, gonadal, and adrenal hormones. J Clin Endocrinol Metab 1989;69:1256-1260.

62. Ng JP, Hubert GW, Justice JB. Increased stimulated release and uptake of dopamine in nucleus accumbens after repeated cocaine administration as measured by in vivo voltammetry. J Neurochem 1991;56:1485-1492.

63. National Institute on Drug Abuse. National survey results on drug use from The Monitoring the Future Study, 1975-1992. Government Publication Number 93-3597, 1993.

64. O'Brien CP, Childress AR, Arndt IO, McLellan AT, Woody GE, Maany I. Pharmacological and behavioral treatments of cocaine dependence: controlled studies. J Clin Psychiatry 1988;49(Suppl):17-22.

65. Ostrea EM, Brady M, Gause S, Raymundo AL, Stevens M. Drug screening of newborns by meconium analysis: a large-scale, prospective, epidemiologic study. Pediatrics 1992;89:107-113.

66. Parsons LH, Smith AD, Justice JB. Basal extracellular dopamine is decreased in the rat nucleus accumbens during abstinence from chronic cocaine. Synapse 1991;9:60-65.

67. Perez-Reyes M, Jeffcoat AR. Ethanol/cocaine interaction: cocaine and cocaethylene plasma concentrations and their relationship to subjective and cardiovascular effects. Life Sci 1992;51:553-563.

68. Pettit H, Justice J Jr. Dopamine in the nucleus accumbens during cocaine self-administration as studied by in vivo microdialysis. Pharmacol Biochem Behav 1989;34:899-904.

69. Pettit HO, Justice JB. Effect of dose on cocaine self-administration behavior and dopamine levels in the nucleus accumbens. Brain Res 1991;539:94-102.

70. Pettit HO, Pan H-T, Parsons LH, Justice JB. Extracellular concentrations of cocaine and dopamine are enhanced during chronic cocaine administration. J Neurochem 1990;55:798-804.

71. Post RM, Lickfeld A, Squillace KM, Contel NR. Drug-environment interaction: context dependency of cocaine induced behavioral sensitization. Life Sci 1981;28:755-760.

72. Pulvirenti L, Maldonado-Lopez R, Koob GF. MNDA receptors in the nucleus accumbens modulate intravenous cocaine but not heroin self-administration in the rat. Brain Res 1992;594:327-330.

73. Racine A, Joyce T, Anderson R. The association between prenatal care and birth weight among women exposed to cocaine in New York City. JAMA 1993;270:13.

74. Reith MEA, de Costa B, Rice KC, Jacobson AE. Evidence for mutually exclusive binding of cocaine, BTCP, GBR 12935, and dopamine to the dopamine transporter. Eur J Pharmacol 1992;227:417-425.

75. Ritz MC, Cone EJ, Kuhar MJ. Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: a structure-activity study. Life Sci 1990;46:635-645.

76. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987;237:1219-1223.

77. Roberts DCS, Loh EA, Vickers G. Self-administration of cocaine on a progressive ratio schedule in rats: dose-response relationship and effect of haloperidol pretreatment. Psychopharmacology 1989;97:535-538.

78. Robinson TE. Stimulant drugs and stress: factors influencing individual differences in the susceptibility to sensitization. In: Kalivas PW, Barnes CD, eds. Sensitization in the nervous systems. Caldwell, NJ: Telford Press, 1988;145-173.

79. Rossetti ZL, Hmaidan Y, Gessa GL. Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur J Pharmacol 1992;221:227-234.

80. Rounsaville BJ, Foley-Anton S, Carroll K, Budde D, Pursoff BA, Gawin F. Psychiatric diagnosis of treatment-seeking cocaine abusers. Arch Gen Psychiatry 1991;48:43-51.

81. Rubin RB, Neugarten J. Cocaine rhabdomyolysis masquerading as myocardial ischemis. Am J Med 1989;86:551-553.

82. Satel SL, Price LH, Palumbo JM, et al. Clinical phenomenology and neurobiology of cocaine abstinence: a prospective inpatient study. Am J Psychiatry 1991;148:1712-1716.

83. Schenk S, Valadez A, McNamara C, et al. Development and expression of sensitization to cocaine's reinforcing properties: role of NMDA receptors. Psychopharmacology 1993;111:332-338.

84. Schuster CR, Gust S. Cocaine: challenges to research. In: Edwards G, Strang J, Jaffe JH, eds. Drugs, alcohol, and tobacco. Oxford: Oxford University Press, 1993;146-155.

85. Seiden LS, Ricaurte GA. Neurotoxicity of methamphetamine and related drugs. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987;359-366.

86. Shimada S, Kitayama S, Lin C-L, et al. Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science 1991;254:576-577.

87. Spealman RD, Bergman J, Madras BK, Melia KF. Discriminative stimulus effects of cocaine in squirrel monkeys: involvement of dopamine receptor subtypes. J Pharmacol Exp Ther 1991;258:945-953.

88. Stewart J, Vezina P. Microinjections of SCH-23390 into the ventral tegmental area and substantia nigra pars reticulata attenuate the development of sensitization to the locomotor activating effects of systemic amphetamine. Brain Res 1989;495:401-406.

89. Volkow ND, Fowler JS, Wolf AP, et al. Changes in brain glucose metabolism in cocaine dependence and withdrawal. Am J Psychiatry 1991;148:621-626.

90. Volkow ND, Mullani N, Gould KL, Adler S, Krajewski K. Cerebral blood flow in chronic cocaine users: a study with positron emission tomography. Br J Psychiatry 1988;152:641-648.

91. Weddington WW, Brown BS, Haertzen CA, et al. Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. Am J Drug Alcohol Abuse 1991;17:137-152.

92. Weed MR, Vanover KE, Woolverton WL. Reinforcing effect of the D1 dopamine agonist SKF 81297 in rhesus monkeys. Psychopharmacology 1993;113:51-52.

93. Weiss F, Markou A, Lorang MT, Koob GF. Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. Brain Res 1992;593:314-318.

94. Weiss F, Paulus MP, Lorang MR, Koob GF. Increases in extracellular dopamine in the nucleus accumbens by cocaine are inversely related to basal levels: effects of acute and repeated administration. J Neurosci 1992;12:4372-4380.

95. Winger G, Skjoldager P, Woods JH. Effects of buprenorphine and other opioid agonists and antagonists on aflentanil- and cocaine-reinforced responding in rhesus monkeys. J Pharmacol Exp Ther 1992;261:311-317.

96. Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol Rev 1987;94:469-492.

97. Witkin JM, Nichols DE, Terry P, Katz JL. Behavioral effects of selective dopaminergic compounds in rats discriminating cocaine injection. J Pharmacol Exp Ther 1991;257:706-713.

98. Woody GE, McLellan AT, Luborsky L, O'Brien CP. Sociopathy and psychotherapy outcome. Arch Gen Psychiatr 1985;42:1081-1086.

99. Woolverton WL. Effects of a D1 and a D2 dopamine antagonist on the self-administration of cocaine and piribedil by rhesus monkeys. Pharmacol Biochem Behav 1986;24:531-535.

100. Woolverton WL, Virus RM. The effects of a D1 and a D2 dopamine antagonist on behavior maintained by cocaine or food. Pharmacol Biochem Behav 1989;32:691-697.

101. Yi S-J, Johnson KM. Effects of acute and chronic administration of cocaine on striatal uptake, compartmentalization and release of [3H]dopamine. Neuropharmacology 1990;29:475-486.